Drug Details

General Information of the Drug (ID: DR0445)
Name
Clarithromycin
Synonyms
clarithromycin; 81103-11-9; Biaxin; 6-O-Methylerythromycin; Klaricid; 6-O-Methylerythromycin a; Clarithromycine; Clathromycin; Abbott-56268; Erythromycin, 6-O-methyl-; A-56268; Macladin; Clarith; Klacid; Kofron; Veclam; Clarithromycinum; Naxy; TE-031; Biaxin XL; UNII-H1250JIK0A; Clarithromycin identity; C38H69NO13; (3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-(((2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-14-ethyl-12,13-dihydroxy-4-(((2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2H-pyran-2-yl)oxy)-7-methoxy-3,5,7,9,11,13-hexamethyloxacyclotetradecane-2,10-dione; Prevpac; CHEBI:3732; H1250JIK0A; Claritromicina; Abbotic; Astromen; Bicrolid; Clacine; Clambiotic; Claribid; Claricide; Claridar; Claripen; Fromilid; Heliclar; Klaciped; Mabicrol; Clacee; Clacid; Clarem; Crixan; Cyllid; Klabax; Klarid; Klarin; Maclar; Zeclar; Helas; Mavid; Adel; Biaxin filmtab; Klax; Biaxin HP; Biaxin xl filmtab; Klaricid Pediatric; CLA; Clarithromycin extended release; DRG-0099; Klaricid H.P.; CTY; SMR000466382; Clarithromycine [INN-French]; Clarithromycinum [INN-Latin]; Claritromicina [INN-Spanish]; SR-05000001992; 116836-41-0; Clarithromycin (Biaxin, Klacid); clarithromycina; Cyllind; CCRIS 8833; Klaricid XL; HSDB 8055; (14R)-14-Hydroxyclarithromycin; TE031; (3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyl-tetrahydropyran-2-yl]oxy-14-ethyl-12,13-dihydroxy-4-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyl-tetrahydropyran-2-yl]oxy-7-methoxy-3,5,7,9,11,13-hexamethyl-oxacyclotetradecane-2,10-dione; (3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-12,13-dihydroxy-4-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-7-methoxy; Clarithromycin,(S); Biaxin (TN); Clarithromycin, 97%; Spectrum_000089; CPD000466382; Clarithromycin [USAN:USP:INN:BAN:JAN]; SpecPlus_000559; 6-O-methyl erythromycin; O(6)-methylerythromycin; CLA;; Spectrum2_001668; Spectrum3_001667; Spectrum4_000629; Spectrum5_001729; 6-0-methylerythromycin A; CHEMBL1741; SCHEMBL38125; BSPBio_003453; KBioGR_001218; KBioSS_000509; MLS000759516; MLS001201751; MLS001424066; BIDD:GT0200; DivK1c_006655; SPECTRUM1504231; SPBio_001855; Lactoferrin B & Clarithromycin; Lactoferrin H & Clarithromycin; DTXSID3022829; Clarithromycin & Interleukin-12; CLM & IL-12; GTPL10903; KBio1_001599; KBio2_000509; KBio2_003077; KBio2_005645; KBio3_002673; ANX-015; SDP-015; Clarithromycin (JP17/USP/INN); Clarithromycin, >=95% (HPLC); Clarithromycin, >=98% (HPLC); HMS1922H09; HMS2051G18; HMS2090O11; HMS2094M05; HMS2231A08; HMS3715J17; Pharmakon1600-01504231; EBD13493; BDBM50404044; CCG-39086; LMPK04000014; MFCD00865140; NSC758704; s2555; ZINC85534098; AKOS015894242; CS-2576; DB01211; MCULE-7168853332; NC00140; NSC 758704; NSC-758704; NCGC00178054-01; NCGC00178054-06; (3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-12,13-dihydroxy-4-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-7-methoxy-3,5,7,9,11,13-hexamethyl-oxacyclotetradecane-2,10-dione; H781; HY-17508; SBI-0206716.P001; Clarithromycin 100 microg/mL in Acetonitrile; C06912; D00276; J10130; AB00053394-10; AB00053394-12; AB00053394-13; AB00053394_14; AB00053394_15; 103C119; Q118551; Q-200870; SR-05000001992-1; SR-05000001992-2; BRD-K49668410-001-07-1; BRD-K49668410-001-18-8; Clarithromycin, European Pharmacopoeia (EP) Reference Standard; Clarithromycin, United States Pharmacopeia (USP) Reference Standard; Clarithromycin Identity, United States Pharmacopeia (USP) Reference Standard; Clarithromycin, Ready Made Solution, 50 mg/mL in DMSO, 0.2 mum filtered; Clarithromycin for peak identification, European Pharmacopoeia (EP) Reference Standard; Clarithromycin, Pharmaceutical Secondary Standard; Certified Reference Material; (3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-{[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl]oxy}-14-ethyl-12,13-dihydroxy-4-{[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2H-pyran-2-yl]oxy}-7-methoxy-3,5,7,9,11,13-hexamethyloxacyclotetradecane-2,10-dione (non-preferred name); (3R,4S,5S,6R,7R,9R,11S, 12R,13S,14S)-6-{[(2S,3R,4S,6R)- 4-dimethylamino-3-hydroxy-6-methyloxan-2-yl]oxy}-14-ethyl-12,13-dihydroxy- 4-{[(2R,4S,5S,6S)-5-hydroxy-4-methoxy-4,6- dimethyloxan-2-yl]oxy}-7-methoxy-3,5,7,9,11,13-hexamethyl-1- oxacyclotetradecane-2,10-dione
    Click to Show/Hide
Molecular Type
Small molecule
Disease Bacterial infection [ICD-11: 1A00-1C4Z] Approved [1]
Investigative
Structure
Click to Download Mol
2D MOL

3D MOL

ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 3: high solubility and low permeability
Bioavailability
55% of drug becomes completely available to its intended biological destination(s)
Clearance
The drug present in the plasma can be removed from the body at the rate of 7.3 mL/min/kg
Elimination
35% of drug is excreted from urine in the unchanged form
Half-life
The concentration or amount of drug in body reduced by one-half in 2.8 hours
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 11.13677 micromolar/kg/day
Unbound Fraction
The unbound fraction of drug in plasma is 0.23%
Vd
Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 1.5 L/kg
Water Solubility
The ability of drug to dissolve in water is measured as 2 mg/mL
    Click to Show/Hide
    Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product
Formula
C38H69NO13
PubChem CID
84029
Canonical SMILES
CCC1C(C(C(C(=O)C(CC(C(C(C(C(C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N(C)C)O)(C)OC)C)C)O)(C)O
InChI
1S/C38H69NO13/c1-15-26-38(10,45)31(42)21(4)28(40)19(2)17-37(9,47-14)33(52-35-29(41)25(39(11)12)16-20(3)48-35)22(5)30(23(6)34(44)50-26)51-27-18-36(8,46-13)32(43)24(7)49-27/h19-27,29-33,35,41-43,45H,15-18H2,1-14H3/t19-,20-,21+,22+,23-,24+,25+,26-,27+,29-,30+,31-,32+,33-,35+,36-,37-,38-/m1/s1
InChIKey
AGOYDEPGAOXOCK-KCBOHYOISA-N
CAS Number
CAS 81103-11-9
ChEBI ID
CHEBI:3732
TTD Drug ID
D0Z1ZM
DrugBank ID
DB01211
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug
          Plaunotol      Croton sublyratus     Click to Show/Hide the Molecular Data of This NP
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [2]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    In-vivo Model Specific-pathogen-free, 5-week-old male Mongolian gerbils were orally inoculated with 2 mL of bacterial suspension having a density of 1 * 108 cfu/mL.
                    Experimental
                    Result(s)		 Plaunotol and clarithromycin combination exhibited synergistic effects in the treatment of diseases associated with clarithromycin-resistant H. pylori.
Target and Pathway
Target(s) Bacterial 50S ribosomal RNA (Bact 50S rRNA)  Molecule Info  [3]
Cannabinoid receptor 2 (CB2)  Molecule Info 
Pyruvate kinase PKM  Molecule Info 
References
Reference 1 Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
Reference 2 Effect of plaunotol in combination with clarithromycin against clarithromycin-resistant Helicobacter pylori in vitro and in vivo. J Antimicrob Chemother. 2007 Nov;60(5):1060-3.
Reference 3 Structural basis for the interaction of antibiotics with the peptidyl transferase centre in eubacteria. Nature. 2001 Oct 25;413(6858):814-21.
 Download Picture         KEGG Link